Will be interesting to hear how the data is interpreted and conclusions. For all 3 cycles relative change in Arikcase FEV1 is less than TOBI, however Arikace off-cycle data inclines where as Tobi declines. This incline is consistent with the PII Arikace extended study that Insmed was excited about....
In addition this is big..
"This early review of data is encouraging. ARIKACE has the potential to be the first once-daily treatment, as compared with the current treatment regimens that require multiple dosing each day. Once-daily treatment may significantly enhance patient convenience and compliance," stated Bonnie Ramsey, MD, Seattle Children's Hospital, Director, Cystic Fibrosis Therapeutics, Development Network Coordinating Center and Chair of the study Steering Committee.
There is a 50% adherence among children when using inhaled antibiotics which materially affects treatment. Once a day with Arikace will increase adnerence and thus Pa treatment.